Hepatocellular carcinoma (HCC), a leading cause of cancer-related mortality worldwide, is driven by complex interactions between genetic mutations and reversible epigenetic alterations. Among these, aberrant DNA methylation, histone modifications, and dysregulated noncoding RNAs (ncRNAs) play central roles in hepatocarcinogenesis, tumor progression, and therapy resistance. Epigenetic changes not only regulate key oncogenic pathways, including JAK/STAT and RAS, but also contribute to tumor immune evasion and heterogeneity. Unlike genetic mutations, epigenetic alterations are reversible, offering unique opportunities for therapeutic targeting. This review highlights recent advances in understanding the epigenetic landscape of HCC, identifies promising biomarkers for early detection and prognosis, and evaluates emerging epigenetic therapies (including DNMT, HDAC, and BET inhibitors as well as ncRNA-based strategies). Although these therapies have shown tumor-suppressive or treatment-sensitizing effects in preclinical models, their clinical translation remains limited by modest efficacy, small early-phase trials, treatment-related adverse events, and insufficient biomarker-guided patient selection. These insights may support more precise diagnostic and therapeutic strategies for HCC.

Metabolic dysfunction-associated fatty liver disease (MAFLD) is now recognized as a leading form of chronic liver disease globally and is strongly associated with metabolic abnormalities. Traditionally, the pathogenesis of MAFLD has mainly been attributed to genetic susceptibility and unhealthy lifestyles (such as high-calorie diets and sedentary behavior). However, in recent years, environmental factors, especially air pollution, have been confirmed as independent risk factors and important promoting factors for MAFLD development and further disease progression. This review summarizes current epidemiological findings on the link between air pollution exposure and MAFLD, while exploring its potential biological mechanisms involving systemic inflammation, oxidative stress, immune alteration, genetic risk, and epigenetic regulation underlying the relationship between air pollution and hepatic steatosis. It also reviews the additive interaction between air pollution and lifestyle or socioeconomic factors in MAFLD. Finally, we also discuss multilevel strategies spanning individual-, community-, national-, and global-level cooperation to address the increasing public health burden caused by air pollution. Therefore, incorporating the assessment and control of air pollution into the comprehensive strategies for MAFLD prevention and treatment has important scientific value and public health significance.

Friedreich's Ataxia (FA) is a leading form of hereditary ataxia caused by autosomal recessive mutations in frataxin (FXN). GAA triplet repeat expansions lead to lower levels of FXN expression, abnormal influx of iron into mitochondria and damage to the nervous system. Patients typically present before the second decade with loss of muscular function, speech impediments, and cardiomyopathy. At later stages, vision loss typically manifests. Work is underway to develop gene therapies that address the cardiac and CNS manifestations, but their routes of administration do not lead to efficient transduction of the retina. The purpose of this study was to develop a more direct approach for treating the ocular phenotype of FA which includes loss of retinal ganglion cells (RGCs), thinning of the retinal nerve fiber layer (RNFL), optic nerve atrophy, and loss of visual field. We generated two novel conditional knock-out (KO) models, mRx-Fxn KO and Pou4f2-Fxn KO mice, wherein Fxn is ablated in all retinal cells or RGCs, respectively and showed that FXN deficiency led to retinal dystrophy in both models. Gene supplementation via intravitreal injection of a novel AAV2-based capsid carrying FXN partially preserved retinal structure and/or function in both models, establishing proof-of-concept for this therapeutic strategy.